
BioSpect
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

Major breakthrough in the fight against antibiotic resistance

30 November -0001 | News | By BioSpectrum Bureau

Major breakthrough in the fight against antibiotic resistance



Cadila pharmaceuticals limited, one of India's largest privately held pharmaceuticals company and UK based antibiotics discovery major, Helperby Therapeuticshave signed a joint agreement on Antibiotic Drug Resistance research and Development.

Described as the most important innovation in the discovery of new antibiotics since Alexander Fleming's original breakthrough more than 80 years ago, this announcement is a major breakthrough in the fight against resistance with the discovery of patented 'resistance breaker' compounds.

These new compounds are called Antibiotic Resistance breaker is combined with an old obsolete antibiotic, it can rejuvenate it and make it active against highly resistance bacteria. Antibiotic resistance Breakers can potentially rescue several different classes of antibiotics. Furthermore, this approach requires the developments of fewer novel compounds, is less risky and less costly than the traditional "one antibiotic" route.

On this occasion, Cadila Pharmaceutical's Chairman and Managing Director Dr. Rajiv I Modi said, "The Founder Chairman of our company, Shri I A Modi, believed in providing affordable medicines for the masses through innovative and cutting-edge research & development (R&D). This discovery will open new avenues against resistant organism and is very timely in view of global concerns about rapidly growing bacterial resistance against current antibitoics. Cadila's pharmaceuticals's collaboration with Helperby can help the mankind win the battle against the microbes and hopefully save millions of lives in coming years."

Helperby's Chief Scientific Officer Professor Anthony Coates said, "The emergence and spread of drug-resistant pathogens has accelerated whilst the pipeline for new anti-microbial drugs has all put run dry - this exciting and timely partnership with Cadila Pharmaceuticals offers us all hope."

Â

Travelling with the UK's trade Delegation to India led by Prime Minister David Cameron, Helperby signed its first major licensing deal with Indian pharma giant Cadila pharmaceuticals to take the compound through further clinical trials, approvals and into commercialization - Helperby will supply Cadila Pharmaceuticals Ltd. with Antibiotic ResistanceÂ Breakers while Cadila Pharmaceuticals Ltd. will develop the combination with old antibiotics. The deal value was undisclosed but could contribute to Helperby scaling up in UK to a potential $500 million operation, creating employment for 500-1000 persons by 2019.

UK's Prime Minister Cameron said, "The life sciences industry is the jewel in the crown for the UK economy, consistently growing and achieving new breakthroughs. "Today's deal between Helperby and Cadila Pharmaceuticals on antibiotic

resistance research is another great example of UK-India collaboration helping both our countries to succeed in the global race. And it's just a step forward for medical research it also has the potential to create up to 1,000 highly skilled jobs in the UK by 2019."

Â

Â